Navellier & Associates Inc Catalyst Pharmaceuticals, Inc. Transaction History
Navellier & Associates Inc
- $756 Million
- Q2 2025
A detailed history of Navellier & Associates Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Navellier & Associates Inc holds 12,524 shares of CPRX stock, worth $257,117. This represents 0.04% of its overall portfolio holdings.
Number of Shares
12,524
Previous 12,524
-0.0%
Holding current value
$257,117
Previous $303,000
10.56%
% of portfolio
0.04%
Previous 0.05%
Shares
11 transactions
Others Institutions Holding CPRX
# of Institutions
386Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$384 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$180 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$112 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$66.8 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$65.4 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.11B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...